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Summary We have reported that rebamipide, a gastroprotective drug, suppresses indomethacin-
induced gastric mucosal injury in humans and rats. However, the mechanisms of the cyto-
protective actions of rebamipide have not been fully addressed. In the present study, we
determined mRNA expression profile of the gastric mucosa treated with indomethacin in rats,
and investigated the cytoprotective effects of rebamipide against indomethacin-induced injury
with a high-density oligonucleotide array (Rat Toxicology U34 GeneChip array). Gastric
epithelial cells were obtained by laser-assisted microdissection. Data analysis was performed with
a GeneChip Operating Software, GeneSpring software 7.0, and Ingenuity Pathway Analysis.
Among 1,031 probes, the expression of 160 probes (15.5%) showed at least 2.0-fold up-
regulation (158 probes) and down-regulation (2 probes) 2 h after indomethacin administration
in comparison with the vehicle-treated rats. The pathway analysis of the up-regulated 123
probes identified the network with a highly significant score, which consisted of known clusters
of cell death, cancer, and endocrine system disorders. We succeeded in listing 10 genes that were
up-regulated by the treatment with indomethacin and that were down-regulated by rebamipide,
including growth arrest and DNA damage-induced 45α. In conclusion, we demonstrated that
cell death, especially apoptosis, pathway is involved in the pathogenesis of indomethacin-
induced gastric mucosal injury, and that inhibition of apoptosis-related genes is possibly
important for the cytoprotective effect of rebamipide against this injury.
Key Words: cytoprotection, gastric injury, indomethacin, transcriptome, rebamipide
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) including
aspirin and indomethacin have been widely used clinically
as anti-inflammatory, analgestic agents, but it has been
documented that NSAIDs cause gastrointestinal erosions
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and ulcers as adverse effects [1, 2]. Although it has been
proposed that a deficiency of endogenous prostaglandins
due to inhibition of cyclooxygenase by NSAIDs is involved
in these effects [3], the exact pathogenic mechanism remains
to be elucidated. Recently, several groups including us reported
that rebamipide, a gastroprotective drug, significantly reduced
gastric mucosal injury induced by indomethacin in rodents
[4–7] and humans [8, 9]. We firstly reported that protective
effects of rebamipide against indomethacin-induced gastric
mucosal injury may result from its antioxidant effect [4]. In
addition, we have demonstrated the gastric cytoprotection
induced by rebamipide from a double blind comparative
study in healthy volunteers [8].
More recently, we investigated the effect of rebamipide on
gene expression in cultured rat gastric mucosal (RGM1)
cells exposed to indomethacin [10]. By the analysis using
DNA microarray and real-time PCR, we confirmed that the
expression of growth arrest and DNA damage-induced 45α
(GADD45α) in RGM1 cells is enhanced by the exposure to
indomethacin and this enhancement is markedly inhibited by
rebamipide. However, the effects of rebamipide on gastric
mucosal gene expression in vivo have not been fully
addressed. In order to characterize the cytoprotective effects
of rebamipide on indomethacin-induced gastric mucosal
injury, we developed acute gastric mucosal injury induced
by indomethacin in rats and measured comprehensive
changes in mRNA expression using DNA microarray in the
absence and presence of rebamipide.
Materials and Methods
Reagents
All chemicals were prepared immediately before use.
Rebamipide was a gift from Otsuka Pharmaceutical Co.,
Ltd. (Tokyo, Japan). RNeasy Mini kit was purchased from
QIAGEN (Valencia, CA) and Rat Toxicology GeneChip
U34 array and Eukaryotic Small Sample Target Labeling
Assay kit were from Affymetrix (Santa Clara, CA). All other
chemicals used were of reagent grade.
Preparation of rats for acute gastric mucosal injury induced
by indomethacin
Male Sprague-Dawley rats weighing 190–210 g were
obtained from Keari Co. Ltd. (Osaka, Japan). They were
housed in stainless steel cages with wire bottoms and main-
tained on a 12-h light and 12-h dark cycle with the tempera-
ture and relative humidity of the animal room controlled at
21–23°C and 55–65%, respectively. They were not fed for
18 h prior to the experiments, but were allowed free access
to water. Maintenance of animals and experimental proce-
dures were carried out in accordance with the U.S. National
Institutes of Health Guidelines for the Use of Experimental
Animals. All experiments were approved by the Animal
Care Committee of Kyoto Prefectural University of Medicine
(Kyoto, Japan). Gastric mucosal injury was induced by the
oral administration of 25 mg/kg of indomethacin (Sigma
Chemical Co., St. Louis, MO) suspended in 0.5% carboxy-
methyl cellulose (CMC) solution with a few drops of Tween
80 in a volume of 0.5 ml/100 g body weight [11]. According
to our previous report [4], rebamipide (100 mg/kg) dissolved
in 0.5% CMC solution was given to the rats by intraperito-
neal injection 0.5 h before indomethacin administration. To
evaluate the effect of agents on indomethacin injury, rats
were divided into the following groups: 1) sham-operated
rats receiving 0.5% CMC solution, 2) indomethacin-treated
rats receiving 0.5% CMC solution, 3) sham-operated rats
receiving rebamipide, and 4) indomethacin-treated rats
receiving rebamipide. Each of the groups contained 3 rats.
Laser capture microdissection, isolation of RNA, cDNA
synthesis, cRNA amplification, and GeneChip hybridization
According to our previous report [12], we used laser-
assisted microdissection to obtain cell-specific RNA. Gastric
epithelial cells, located mainly in an upper one-third of
mucosa, were identified on cryostat sections (8 µm) of the
specimens obtained from the stomach of the rat, and the
cells were isolated by laser-assisted microdissection using
an LM200 system (Olympus, Tokyo, Japan). A sample
containing five hundred cells was collected from each
stomach. Our experiments were performed according to the
Affymetrix GeneChip Eukaryotic Small Sample Target
Labeling Assay protocol (Version II). Using this protocol,
we succeeded in obtaining a sufficient amount of biotinylated
cRNA to perform the GeneChip analysis from the small
amount of gastric epithelial cells obtained by laser-captured
microdissection.
Total RNA was extracted from the mixtures of three
samples using a Qiagen RNeasy kit (Qiagen, Valencia, CA)
and treated with DNase to remove any residual genomic
DNA. Briefly, for first strand cDNA synthesis, total RNA
sample (1 µl) mixed with T7-Oligo(dT) promoter primer
was incubated at 70°C in a thermal cycler for 6 min, cooled
to 4°C for 2 min, and reverse transcribed for 1 h at 42°C
with 3 µl of the RT_Premix_1, and cooled to 4°C. Strand
cDNA synthesis was carried out by adding 32.5 µl of
SS_Premix_1, and incubating for 2 h at 16°C. The resulting
cDNA was cleaned up by ethanol precipitation. To perform
in vitro transcription, the dried double-stranded cDNA pellet
was mixed with the following reagents (10 µl): 4 µl DEPC-
treated water, 4 µl premixed NTPs, 1 µl 10× reaction buffer,
and 1 µl 10× enzyme mix, and incubated at 37°C in a water
bath for 6 h. First cycle cRNA was cleaned up using the
RNeasy Mini Protocol for RNA Cleanup from the handbook
accompanying the RNeasy Mini Kit for cRNA purification.
For the second cycle of amplification and labeling, the
cRNA sample was mixed with random primers (0.2 µg/µl),Y. Naito et al.
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incubated at 70°C for 10 min, cooled on ice for 2 min, and
incubated at 42°C for 1 h with 5 µl of the RT_Premix_2.
Second strand cDNA synthesis was carried out by mixing
the sample with by addition of 5 µM T7-Oligo(dT) promoter
primer and incubating at 70°C for 6 min, cooling at 4°C, and
incubating again with 62 µl of SS_Premix_2. The resulting
cDNA was treated with 1 µl T4 DNA polymerase (5 U/µl)
for 10 min at 16°C, and cleaned up by ethanol precipitation.
To perform in vitro transcription and labeling with the
ENZO BioArray High Yield RNA Transcript Labeling Kit,
the dried double-stranded cDNA pellet was incubated at
37°C for 4 h with 40 µl of the following reagents: 22 µl
DEPC-treated water, 4 µl 10× HY reaction buffer, 4 µl 10×
biotin labeled ribonucleotides, 4 µl 10× DTT, 4 µl 10×
RNase inhibition mix, and 2 µl 20× T7 RNA polymerase.
Labeled cRNA target was cleaned up using RNeasy columns.
The fragmentation, hybridization, washing, and staining
were carried out according to the instructions described in the
GeneChip Expression Analysis Technical Manual. GeneChip
arrays were hybridized with the biotinylated products (5 µg/
chip) for 16h at 45°C using the manufacturer’s hybridization
buffer. After washing the arrays, hybridized RNA was
detected by staining with streptavidin-phycoerythrin (6 ×
SSPE, 0.01% Tween-20, pH 7.6, 2 mg/ml acetylated bovine
serum albumin, and 10 µg/ml of streptavidin-phycoerythrin
from Molecular Probes). The DNA chips were scanned
using a specially designed confocal scanner (GeneChip
Scanenr 3000, Affymetrix).
Gene expression analysis
As an initial statistical analysis, we used Affymetrix
GeneChip Operating Software (GCOS) version 1.0. GCOS
analyzes image data and computes an intensity value for
each probe cell. Briefly, mismatch probes act as specificity
controls that allow the direct subtraction of both background
and cross-hybridization signals. To determine the quantitative
RNA abundance, the average of the difference representing
perfect match - mismatch for each gene-specific probe
family is calculated. GCOS showed expression changes
(Increased, Decreased or Marginal) in expression levels
between pairs of profiles (difference analysis). For the
pathway analysis, Gene probe set ID numbers were imported
into the Ingenuity Pathway Analysis software (Ingenuity
Systems, Mountain View, CA). The identified genes were
mapped to genetic networks available in the Ingenuity
database and were then ranked by score. The score is the
probability that a collection of genes equal to or greater than
the number in a network could be achieved by chance alone.
A score of 3 indicates that there is a 1/1000 chance that
the focus genes are in a network due to random chance.
Therefore, scores of 3 or higher have a 99.9% confidence of
not being generated by random chance alone.
Results and Discussion
Analysis for gene expression induced by indomethacin
treatment in rats
In the present study, we used the high-density oligo-
nucleotide microarray technique for mRNA expression
profile of gastric elithelial cells in order to investigate the
mechanism of mucosal injury under the conditions of
indomethacin exposure in vivo. We used the Rat Toxicology
GeneChip U34 array (Affymetrix), which contained 1,031
probes. The present study showed that the expression of
160 probes (15.5%) showed at least a 2.0-fold up-regulation
(158 probes) or down-regulation (2 probes) 2 h after
indomethacin administration in comparison with the vehicle-
treated rats. Selective genes demonstrating alterations
greater than 3.0-fold are listed in the Table 1. Genes
involved in redox-related enzymes (superoxide dismutase 1,
carbonyl reductase 1, glutathione peroxidase 3, glutathione
S-transferase, etc.) and transcription regulators (c-fos
oncogene, etc.) were included.
123 of these up-regulated 158 probes were mapped to
genetic networks as defined by the IPA tool. By the pathway
analysis of the up-regulated 123 probes, 5 networks were
found to be significant in that they had more of the identified
genes present than would be expected by chance (Table 2).
The network 1 shown in Table 2 contained the majority
of these genes, and had a highly significant score of 73,
and consisted of known clusters of cell death, cancer, and
endocrine system disorders. Figure 1 illustrated the association
of the network 1 that was most significantly affected by
indomethacin. These data suggest that the imbalance of gene
expression between apoptotic- and anti-apoptotic genes may
be involved in the pathogenesis of indomethacin-induced
gastric mucosal injury, which was also supported by previous
studies. It has been demonstrated that indomethacin treatment
induces gastric epithelial cell apoptosis in vivo [13, 14] and
in vitro [15, 16]. Recent our study clearly showed apoptotic
cell death of gastric epithelial cells induced by indomethacin
in vitro [10].
In addition, we found two major pathways by the
Ingenuity pathway analysis; glutathione metabolism and
inflammation (Table 3). The genes involved in glutathione
metabolism included glutathione peroxidase 1 and 3, many
types of glutathione S-transferases (GST), and microsomal
glutathione transferase (MGST1, 3) were up-regulated after
the indomethacin exposure. The glutathione metabolism, a
caronical pathway recorded in this analysis, was markedly
affected by indomethacin with a most highest significance of
p =1 . 4 2× 10−7. This induction of these genes may result
from cellular response in gastric epithelial cells against
oxidative stress induced by indomethacin administration, or
from the direct pharmacological effect of indomethacin. The
former hypothesis is supported by several reports [11,Gene Clusters Involved in Rebamipide-Induced Cytoprotection
Vol. 41, No. 3, 2007
205
Table 1. Genes up-regulated at least 3.0-fold in gastric mucosa exposed to indomethacin
Probe Set ID Description
Signal Intensity
sham indomethacin fold difference
M74439mRNA_i_at — 180.1 18371.4 78.79
Y00404_s_at superoxide dismutase 1 298.5 3426.9 10.56
D89070cds_s_at carbonyl reductase 1 347.5 4341.7 9.85
rc_AA859372_s_at — 195.1 1347.0 9.19
X06769cds_g_at FBJ murine osteosarcoma viral oncogene homolog 197.7 1906.8 8.00
rc_AI228738_s_at FK506-binding protein 1a /// FK506 binding protein 2 142.6 922.2 7.46
AFFX_rat_5S_rRNA_at — 124.1 688.1 6.50
rc_AI172411_at glutathione peroxidase 3 477.1 2807.2 6.06
J02844_s_at carnitine O-octanoyltransferase 28.2 103.9 6.06
C06598_at similar to binding protein 298.4 1828.7 4.92
U39208_at cytochrome P450 4F6 578.8 2699.1 4.92
X53428cds_s_at glycogen synthase kinase 3 beta 67.4 267.0 4.59
rc_AI171506_g_at malic enzyme 1 39.9 206.2 4.00
AA848546_at similar to programmed cell death 10 120.2 264.9 4.00
rc_AI176658_s_at heat shock 27kDa protein 1 154.1 553.6 4.00
X07467_at glucose-6-phosphate dehydrogenase 272.0 1103.8 3.73
rc_AI178835_at mitogen activated protein kinase kinase 1 70.0 114.2 3.48
U95727_at DnaJ (Hsp40) homolog, subfamily A, member 2 109.3 238.5 3.48
X04229cds_s_at glutathione S-transferase, mu 1 159.2 578.6 3.48
D63761_g_at ferredoxin reductase 183.9 668.8 3.48
X77117exon#1-3_at Diaphorase 1 248.8 610.0 3.48
rc_AA945054_s_at cytochrome b-5 271.0 1036.7 3.48
K01932_f_at glutathione S-transferase A5 341.3 1250.4 3.48
M57428_s_at ribosomal protein S6 kinase, polypeptide 1 76.2 215.6 3.25
rc_AA848545_at similar to programmed cell death 10 119.0 288.9 3.25
X91988_at signal transducer and activator of transcription 5B 163.4 454.9 3.25
L19998_g_at sulfotransferase family 1A, phenol-preferring, member 1 209.1 605.4 3.25
X63594cds_g_at nuclear factor of kappa light chain gene enhancer 269.1 890.6 3.25
S82820mRNA_s_at glutathione S-transferase Yc2 subunit 282.4 928.6 3.25
U03388_s_at prostaglandin-endoperoxide synthase 1 286.2 572.8 3.25
rc_AI176422_g_at electron-transferring-flavoprotein dehydrogenase 287.5 842.7 3.25
M15114_g_at stearoyl-Coenzyme A desaturase 2 102.8 468.7 3.03
U46118_at cytochrome P450, family 3, subfamily a, polypeptide 13 138.3 355.6 3.03
J05035_at steroid 5 alpha-reductase 1 145.2 544.8 3.03
X62952_at vimentin 163.2 454.5 3.03
M38566mRNA_s_at cytochrome P450, family 27, subfamily a, polypeptide 1 163.5 492.3 3.03
U03491_g_at transforming growth factor, beta 3 175.1 604.8 3.03
M33986mRNA_at cytochrome P450, family 19, subfamily a, polypeptide 1 186.1 427.7 3.03
rc_AA925473_at cell division cycle 42 homolog (S. cerevisiae) 206.3 595.5 3.03
rc_AA859648_at DnaJ (Hsp40) homolog, subfamily B, member 1 
(predicted)
221.0 730.3 3.03
D00636Poly_A_Site#1_s_at diaphorase 1 243.0 1035.5 3.03
L29232_at insulin-like growth factor 1 receptor 244.7 319.3 3.03
X78848cds_f_at glutathione S-transferase A5 291.6 903.7 3.03
X70369_s_at collagen, type III, alpha 1 720.3 1642.2 3.03Y. Naito et al.
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Table 2. Genes in network induced by indomethacin treatment
Network
ID Genes in Network Score Focus 
Genes Top Functions
1 APEX1, COL3A1, CRYAB, CYB5, CYCS, FASN, FOS, GADD45A, GAPD, GPX1,
GSK3B, GSTA1, GSTM1, GSTM2, GSTP1, HSF1, HSPA1B, HSPB1, HSPB6, IL18,
JUN, MAP2K6, MAP3K12, MAPK14, MGST3, MSH2, MYC, ODC1, PAWR,
PPIA, Scd2, SOD2, TGFB3, TOP2A, TRAPPC3
73 35 Cell Death, Cancer, 
Endocrine 
System Disorders
2 ADCYAP1, APOC2, ARD1, BAG2, CANX, CCND2, CDC42, CYP19A1, FBXW11,
FGF6, GEFT, GPR30, GPX3, HSPA8, HSPB8, IGF1R, KSR, LPL, MAP2K1,
MAP2K1IP1, MAPK3, MOS, NAT1, NFKBIA, PBP, PCSK5, POMC, PPP1CB,
PTPRR, RB1, RPS6KB1, SOD1, STIP1, UCN, Ugt2b
23 16 Cell Cycle, 
Cellular Growth and 
Proliferation, Cancer
3 ABCC1, AKR1B1, ANGPTL4, ARG1, CEBPA, CROT, CTH, CYP3A7, CYP51A1,
DECR1, DIA1, EGR2, FASN, FTCD, GAL, GH1, GHRH, GHRL, HSD17B4, IFNG,
Ins1, LPL, ME1, MGST1, MST1R, PPARA, PTPRN, SOCS2, SRD5A1, STAT5B,
THRB, UQCRC1, UQCRC2, UQCRH, VIM
21 15 Organismal Development, 
Nutritional Disease, Lipid 
Metabolism
4 ACOX1, AGT, ANGPTL4, COX7A2, COX8A, CYP17A1, CYP27A1, Cyp2c44,
CYP2E1, DAD1, EHHADH, ETFDH, FKBP1A, GAL, GPX3, GPX4, HADHA,
HADHB, HSD3B1, IDH1, IL4, IL13, IL1R2, LEP, LTC4S, MAOA, PPARG, PTEN,
PTGES, PTGS1, RAB10, STK11, TGFB1, Tgtp, XBP1




5 AHR, AIP, APC, BRF1, BUB1, CAMLG, CCS, CSNK1D, CSNK1E, CYP1A1,
CYP1A2, CYR61, DHFR, DNASE1, EPHX1, FDXR, G6PD, GSK3B, HSPCB,
IFI16, KLF4, MCM7, NFE2, NQO1, PHB, PSMB2, RBL2, RRM2, SHOX, SIM1,
TFDP1, TP53, UBE2B, UBTF, UGT1A6
12 10 Cell Signaling, Drug 
Metabolism, Cell Cycle
Fig. 1. Networks of genes commonly up-regulated after indomethacin administration.Gene Clusters Involved in Rebamipide-Induced Cytoprotection
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17–19], in which lipid peroxidation was enhanced by
indomethacin treatment and indomethacin induced-gastric
mucosal injuries were significantly inhibited by the several
antioxidants  in vivo. The induction of these genes may
indicate the presence of oxidative stress in the gastric mucosa
after the indomethacin administration. Recent investigation
clearly demonstrated that oxidative stress was induced by
the irreversible inactivation of gastric peroxidase via the direct
interaction between indomethacin and gastric peroxidase
[20]. Up-regulation of GST genes is also supported by van
Lieshout et al. [21], who have demonstrated the induction
of GST in the stomach by indomethacin in rats. As GST is
a family of detoxifying enzymes, the enhancement of GSTs
in the stomach may explain in part the anticarcinogenetic
properties of nonsteroidal anti-inflammatory drugs including
indomethacin.
In addition to glutathione metabolism, inflammation-
associated genes were also up-regulated after the indo-
methacin treatment, which included fos, jun, MAP kinase,
MAP kinase kinase, MAP kinase kinase kinase, NF-κB,
Table 3. High level functions most significantly associated with indomethacin-induced gene expression profile
Canonical Pathway Focus Gene Significance Genes
Glutathione Metabolism 11/61 1.42 × 10−7 G6PD, GPX1, GPX3, GSTA1, GSTK1, GSTM1, GSTM2, GSTP1, 
GSTT2, MGST1, MGST3
IL-6 Signaling 10/68 3.97 × 10−6 CYP19A1, FOS, HSPB1, IL1R, JUN, MAP2K1, MAP2K6, MAPK3, 
MAPK14, NF-KBIA
B Cell Receptor Signaling 10/114 3.78 × 10−4 CDC42, GSK3B, JUN, MAP2K1, MAK2K6, MAP3K12, MAPK3, 
MAPK14, NFKBIA, RPS6K131
Tryptophan Metabolism 9/98 5.42 × 10−4 CYP19A1, CYP1A1, CYP1A2, CYP3A7, CYP51A1, EHHADH, 
HADHA, HSD17B4, MADA
Table 4. Genes up-regulated at least 2.0-fold in indomethacin treatment and down-regulated at least 1.5-fold in rebamipide treatment










rc_AI228738_s_at FK506-binding protein 1a /// FK506
binding protein 2
142.6 922.2 547.4 7.46 0.66
rc_AI172411_at glutathione peroxidase 3 477.1 2807.2 1892.2 6.06 0.66
rc_AA900413_at dihydrofolate reductase 95.0 349.9 262.4 3.73 0.57
U03388_s_at prostaglandin-endoperoxide synthase 1 286.2 572.8 673.0 3.25 0.62
X63594cds_g_at nuclear factor of kappa light chain gene
enhancer in B-cells inhibitor, alpha
269.1 890.6 526.8 3.25 0.62
U03491_g_at transforming growth factor, beta 3 175.1 604.8 164.2 3.03 0.38
AFFX-DapX-M_at — 20.7 70.2 42.2 2.83 0.62
rc_AI178204_at — 55.6 86.5 78.4 2.46 0.66
D31838_at wee 1 homolog (S. pombe) (predicted) 91.2 174.8 102.0 2.00 0.66
rc_AI070295_g_at growth arrest and DNA-damage-
inducible 45 alpha
85.4 168.6 109.5 2.00 0.62
Table 5. The levels of mRNA expression for growth arrest and DNA damage-inducible gene (GADD45α)






Ratio Change Ratio Change
rc_AI070295_at 31.7 61.4 23.5 1.87 NC 0.44 D
rc_AI070295_g_at 85.4 168.6 109.5 2.00 I 0.62 D
L32591mRNA_at 284.3 627.3 556.1 2.64 I 0.93 NC
L32591mRNA_g_at 76.5 112.8 60.1 1.52 NC 0.87 NCY. Naito et al.
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Table 6. Genes up-regulated at least 1.5-fold in rebamipide treatment in rats





D89070cds_s_at carbonyl reductase 1 347.5 5844.1 4.00
rc_AA859372_s_at — 195.1 1366.7 4.00
rc_AI171506_g_at malic enzyme 1 39.9 360.8 4.00
X07467_at glucose-6-phosphate dehydrogenase 272.0 1660.4 3.48
M58040_at Transferrin receptor 40.9 208.2 3.25
D00680_at glutathione peroxidase 3 27.2 216.5 2.83
D16308_at cyclin D2 203.0 1238.3 2.83
M19533mRNA_i_at peptidylprolyl isomerase A 81.9 548.2 2.83
U09793_at Kirsten rat sarcoma viral oncogene homologue 2 (active) 29.2 184.9 2.64
rc_AI172411_at glutathione peroxidase 3 477.1 2975.9 2.64
U03388_s_at prostaglandin-endoperoxide synthase 1 286.2 1255.3 2.64
D88190_s_at serine/threonine kinase 39, STE20/SPS1 homolog (yeast) 439.2 1506.9 2.30
rc_AI171506_at malic enzyme 1 52.6 312.1 2.30
U27518_at UDP-glucuronosyltransferase 57.8 242.2 2.30
X70369_s_at collagen, type III, alpha 1 720.3 3777.7 2.30
rc_AA892234_at microsomal glutathione S-transferase 3 (predicted) 480.5 1595.6 2.14
U68562mRNA#2_s_at heat shock protein 1 (chaperonin) 108.6 466.8 2.14
X62952_at vimentin 163.2 484.5 2.14
X53428cds_s_at glycogen synthase kinase 3 beta 67.4 209.3 2.00
M24604_g_at proliferating cell nuclear antigen 192.1 1020.3 2.00
rc_AA963449_s_at cytochrome P450, subfamily 51 58.7 229.2 2.00
AB010428_s_at cytosolic acyl-CoA thioesterase 1 118.5 519.1 1.87
AF007107_s_at cytochrome b-5 90.6 315.6 1.87
AFFX_Rat_GAPDH_5_at glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 202.0 752.8 1.87
AFFX_Rat_GAPDH_M_at glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 493.0 1994.0 1.87
D89375_s_at sulfotransferase family 1B, member 1 173.4 662.9 1.87
M17701_s_at glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 693.4 2398.9 1.87
rc_AA899854_at topoisomerase (DNA) 2 alpha 224.1 816.7 1.87
S82820mRNA_s_at glutathione S-transferase Yc2 subunit 282.4 1092.5 1.87
U95727_at DnaJ (Hsp40) homolog, subfamily A, member 2 109.3 363.8 1.87
AJ222813_s_at interleukin 18 82.2 374.6 1.74
D89069_f_at carbonyl reductase 1 705.1 3095.2 1.74
U46118_at cytochrome P450, family 3, subfamily a, polypeptide 13 138.3 386.3 1.74
AFFX_Rat_GAPDH_3_at glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 964.7 3448.5 1.62
D17310_s_at 3-alpha-hydroxysteroid dehydrogenase 129.1 484.7 1.62
rc_AA926193_at sulfotransferase family, cytosolic, 1C, member 2 523.4 1761.8 1.62
rc_AI171243_at replication protein A3 (predicted) 61.7 195.5 1.62
rc_AI175959_at v-jun sarcoma virus 17 oncogene homolog (avian) 121.3 345.4 1.62
rc_AI177256_at moderately similar to NP_795929.1 RIKEN cDNA 8030475D13 512.5 2134.4 1.62
rc_AA900199_s_at NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 269.7 775.7 1.52
rc_AA945054_s_at cytochrome b-5 271.0 1003.5 1.52
rc_AA945867_at v-jun sarcoma virus 17 oncogene homolog (avian) 88.3 307.0 1.52
rc_AI013834_s_at hydroxysteroid (17-beta) dehydrogenase 4 127.8 415.9 1.52
Z78279_g_at collagen, type 1, alpha 1 593.3 2153.6 1.52Gene Clusters Involved in Rebamipide-Induced Cytoprotection
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and STAT. Ingenuity Pathway analysis showed that IL-6
signaling was associated with these genes with a significance
of p =3 . 9 7× 10−6. Although it has been reported that IL-6
play a significant role in pathogenesis of gastric inflammation
induced by Helicobacter pylori [ 22,  23], there were no
reports investigating the role of IL-6 in indomethacin-
induced gastric mucosal injury. Further studies will be
necessary to clarify the role of this signaling in the pathogenesis
of indomethacin-induced gastric injury.
Effects of Rebamipide on Gene Expression Affected by
Indomethacin in Rats
We succeeded in listing 10 genes including 2 EST based on
the following criteria: genes that are up-regulated at least 2.0-
fold after 2-h treatment with indomethacin in comparison with
the vehicle-treated rats, and also genes that are down-
regulated at least 1.5-fold after pretreatment with rebamipide
in comparison with pretreatment with vehicle prior to 2-h
exposure to indomethacin (Table 4). These genes were
involved in regulators of NF-κB cascade (FK506-binding
protein 1a, and IkBα), oxidative stress response (glutathione
peroxidase 3, dihydrofolate reductase), and cell cycle
regulators {transforming growth factor, wee 1, and growth
arrest and DNA-damage-inducible 45α (GADD45α)}.
The down-regulation of NF-κB cascade by rebamipide is in
line with the previous report, in which anti-inflammatory effect
of rebamipide is derived from the inhibition of NF-κB cascade
[24, 25]. The inhibition of the oxidative stress-related genes
by rebamipide is also consistent with the data that rebamipide
is powerful scavenger of oxygen-derived free radicals [26,
27]. These data suggest that cytoprotection by rebamipide
against indomethacin-induced gastric injury may be related
to its anti-inflammatory and anti-free radical properties.
Finally, in the Rat Toxicology U34 array, four probe sets
were included for the GADD45α gene: rc_AI070295_at, rc_
AI070295_g_at, L32591mRNA_at, and L32591mRNA_g_at.
The expression of all four probes was up-regulated at least
1.5-fold after indomethacin exposure and down-regulated
by the pretreatment with rebamipide (Table 5). The present
data was in line with our previous data obtained from the
in vitro study, showing that the expression of GADD45α
was enhanced by indomethacin exposure and that this
enhancement was markedly inhibited by the treatment with
rebamipide [10]. These changes were also confirmed by
real-time PCR using a gastric mucosal cell line [10]. These
data obtained from in vivo and in vitro studies strongly
suggest that GADD45α play a crucial role in indomethacin-
induced cell death, and that cytoprotective action of rebamipide
may, in part, be mediated by this molecule.
Effects of Rebamipide Treatment on Gene Expression in
Normal Rats
Among the 1031 probes, the number of genes, the expression
levels of which increased more than 1.5-fold in rebamipide-
treated mucosa, was 44 including 1 EST. Many investigations
have demonstrated several factors, including prostaglandins,
growth factors, antioxidants, and heat shock proteins, to
exert cytoprotection against gastric injuries. Among these
cytoprotective factors, the expression of prostaglandin-
endoperoxide synthase 1 (cyclooxygenase 1 (cox-1)) was
up-regulated by the treatment with rebamipide in vivo as
shown in Table 6. By an in vitro study using gastric epithelial
cells, rebamipide treatment increased the expression of cox-1
by 1.32-fold compared to vehicle treatment (data not
shown). These results suggest that cytoprotective effects of
rebamipide may be derived, in part, from Cox-1 or its generated
prostaglandins. Tarnawski et al. [28] previously reported that
rebamipide significantly upregulated the proangiogenic genes
encoding vascular endothelial growth factor (VEGF), heparin
binding epidermal growth-like factor (HB-EGF), fibroblast
growth factor receptor-2 (FGFR2), and cyclooxygenase-2
(Cox2), as well as growth promoting genes, including
insulin growth factor-1 (IGF-1). However, the enhanced
expression of these genes was not re-confirmed in the
present study. These difference may be derived the difference
between experimental conditions of in vivo (the present
study) and in vitro shown by Tarnawski et al. [28].
In conclusion, the present study using GeneChip analysis
demonstrated the enhanced expression of apoptosis- and
inflammation-related genes in the gastric epithelial cells
exposed to indomethacin in vivo, and that inhibition of
apoptosis-related genes, especially GADD45α by rebamipide
is possibly important for its cytoprotective effect against this
injury.
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